TISSIUM Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
140
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
14
TISSIUM General Information
Description
Developer of biodegradable programmable polymer technology designed for tissue reconstruction and adaptable for use in multiple clinical areas. The company's technology uses biomorphic reconstructive polymers for biodegradable sealants and adhesives for surgical-wound closure that are non-toxic, designed to bind strongly to tissues and deliver immediate wound closure within the environments of the body, enabling surgeons to treat patients with a polymer that can be used in the fields of tissue repair and localized drug delivery.
Contact Information
Website
www.tissium.comCorporate Office
- 18 Avenue Léon Gaumont
- 75020 Paris
- France
Corporate Office
- 18 Avenue Léon Gaumont
- 75020 Paris
- France
TISSIUM Timeline
TISSIUM Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 13. Accelerator/Incubator | 15-Jun-2026 | Completed | Generating Revenue | |||
| 12. Later Stage VC (Series D2) | 23-Nov-2025 | Completed | Generating Revenue | |||
| 11. Accelerator/Incubator | 05-Jun-2025 | Completed | Generating Revenue | |||
| 10. Grant | 15-Jun-2023 | Completed | Generating Revenue | |||
| 9. Later Stage VC (Series D) | 23-May-2023 | Completed | Generating Revenue | |||
| 8. Accelerator/Incubator | 01-Feb-2022 | Completed | Generating Revenue | |||
| 7. Later Stage VC (Series C) | 31-Aug-2021 | Completed | Generating Revenue | |||
| 6. Debt - General | 01-Oct-2020 | Completed | Pre-Clinical Trials | |||
| 5. Later Stage VC (Series B) | 20-Nov-2019 | $43M | $79.4M | Completed | Pre-Clinical Trials | |
| 4. Grant | 24-Jan-2018 | $7.26M | $36.4M | Completed | Pre-Clinical Trials |
TISSIUM Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| D Shares | ||||||||
| C Shares | ||||||||
| B Shares | ||||||||
| A2 Shares | 499,998 | $0.010972 | $49.37 | $49.37 | 1x | $49.37 | 2.08% | |
| A Shares | 210,526 | $0.010972 | $41.69 | $41.69 | 1x | $41.69 | 0.88% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
TISSIUM Comparisons
Industry
Financing
Details
TISSIUM Competitors (10)
One of TISSIUM’s 10 competitors is Nico (Surgical Devices), a Formerly VC-backed company based in Indianapolis, IN.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Nico (Surgical Devices) | Formerly VC-backed | Indianapolis, IN | ||||
| Biom'Up | Formerly VC-backed | Saint-Priest, France | ||||
| Artivion | Formerly PE-Backed | Kennesaw, GA | ||||
| Apyx Medical | Corporation | Clearwater, FL | ||||
| Medtronic | Corporation | Minneapolis, MN |
TISSIUM Patents
TISSIUM Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026124775-A1 | Sealing disposable for a medical light application device | Pending | 12-Dec-2024 | ||
| WO-2026125761-A1 | Sealing disposable for a medical light application device | Pending | 12-Dec-2024 | ||
| EP-4744896-A1 | Composition comprising pre-polymer | Pending | 15-Nov-2024 | ||
| WO-2026104575-A1 | Composition comprising pre-polymer | Pending | 15-Nov-2024 | ||
| EP-4745175-A1 | Composition comprising pre-polymer with improved mechanical properties | Pending | 15-Nov-2024 | C08G18/4244 |
TISSIUM Signals
TISSIUM Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| ISALT- Strategic Long Term Equity Investments | PE/Buyout | Minority | ||
| Merieux Equity Partners (Lyon) | PE/Buyout | Minority | ||
| La French Tech | Accelerator/Incubator | |||
| Cathay Capital | PE/Buyout | Minority | ||
| Cathay Health | Venture Capital | Minority |
TISSIUM FAQs
-
When was TISSIUM founded?
TISSIUM was founded in 2013.
-
Where is TISSIUM headquartered?
TISSIUM is headquartered in Paris, France.
-
What is the size of TISSIUM?
TISSIUM has 140 total employees.
-
What industry is TISSIUM in?
TISSIUM’s primary industry is Surgical Devices.
-
Is TISSIUM a private or public company?
TISSIUM is a Private company.
-
What is TISSIUM’s current revenue?
The current revenue for TISSIUM is .
-
How much funding has TISSIUM raised over time?
TISSIUM has raised $271M.
-
Who are TISSIUM’s investors?
ISALT- Strategic Long Term Equity Investments, Merieux Equity Partners (Lyon), La French Tech, Cathay Capital, and Cathay Health are 5 of 14 investors who have invested in TISSIUM.
-
Who are TISSIUM’s competitors?
Nico (Surgical Devices), Biom'Up, Artivion, Apyx Medical, and Medtronic are some of the 10 competitors of TISSIUM.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process